World neurosurgery · 2025
Comparative Efficacy of Plateletpheresis and Rehydration for Managing Secondary Thrombocytosis in the Neurosurgical Intensive Care Unit.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Zuan, Tao Yuqi, Zhu Mingfeng, Yu Tao, Liang Risheng
Аннотация
BACKGROUND: Secondary thrombocytosis (ST) is associated with increased thromboembolic risk in neurocritical care settings; however, its optimal management remains a subject of debate. We aimed to compare the therapeutic efficacy and clinical outcomes of plateletpheresis versus rehydration therapy in patients with ST.
METHODS: A retrospective cohort study was conducted in the neurosurgical intensive care unit (NSICU) of the First Affiliated Hospital of Wannan Medical College from April 2020 to July 2024. A total of 68 patients with ST were enrolled and allocated to the plateletpheresis group (n = 31) or the rehydration group (n = 37). The primary endpoints were changes in complete blood count parameters. Secondary outcomes included NSICU and total hospital length of stay, hospitalization costs, and 3-month modified Rankin Scale scores.
RESULTS: Both interventions demonstrated significant efficacy in managing ST. Plateletpheresis yielded superior cytoreductive effects, with greater reductions in platelet count (64% vs. 55%; P < 0.001) and plateletcrit (65% vs. 55%; P < 0.001) compared to rehydration. In contrast, rehydration produced nonspecific hematological effects, notably a significant decrease in leukocyte subpopulations-neutrophils (55% vs. 25%) and monocytes (50% vs. 17%) (P < 0.001). Clinically, plateletpheresis was associated with lower treatment cycles, shorter NSICU and hospital stays, as well as reduced hospitalization costs. Functional outcomes at 3 months were comparable between the groups.
CONCLUSIONS: Plateletpheresis appears to be the preferred therapeutic approach for rapid platelet reduction in neurocritical patients with ST, offering targeted cytoreduction, a favorable safety profile, and improved resource efficiency. Further validation through multicenter randomized controlled trials is warranted.
METHODS: A retrospective cohort study was conducted in the neurosurgical intensive care unit (NSICU) of the First Affiliated Hospital of Wannan Medical College from April 2020 to July 2024. A total of 68 patients with ST were enrolled and allocated to the plateletpheresis group (n = 31) or the rehydration group (n = 37). The primary endpoints were changes in complete blood count parameters. Secondary outcomes included NSICU and total hospital length of stay, hospitalization costs, and 3-month modified Rankin Scale scores.
RESULTS: Both interventions demonstrated significant efficacy in managing ST. Plateletpheresis yielded superior cytoreductive effects, with greater reductions in platelet count (64% vs. 55%; P < 0.001) and plateletcrit (65% vs. 55%; P < 0.001) compared to rehydration. In contrast, rehydration produced nonspecific hematological effects, notably a significant decrease in leukocyte subpopulations-neutrophils (55% vs. 25%) and monocytes (50% vs. 17%) (P < 0.001). Clinically, plateletpheresis was associated with lower treatment cycles, shorter NSICU and hospital stays, as well as reduced hospitalization costs. Functional outcomes at 3 months were comparable between the groups.
CONCLUSIONS: Plateletpheresis appears to be the preferred therapeutic approach for rapid platelet reduction in neurocritical patients with ST, offering targeted cytoreduction, a favorable safety profile, and improved resource efficiency. Further validation through multicenter randomized controlled trials is warranted.